Science Review Links GLP-1 Drugs to Lower Dementia Risk

A new review in Science finds GLP-1 drugs like semaglutide and tirzepatide are linked to lower dementia risk in people with diabetes, but two large trials showed semaglutide did not slow early Alzheimer’s disease. Researchers say benefits may depend on who takes them and when treatment starts.

A comprehensive review published November 5 in Science evaluated whether GLP-1 receptor agonists — medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — can protect cognitive function. The analysis, led by researchers at the University of Copenhagen and the University of Gothenburg, found a sharp split between observational data and randomized trial results.

Observational Data Link GLP-1 Drugs to Lower Dementia Risk

Analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia among people with type 2 diabetes. However, these studies are observational and cannot determine whether the medications themselves caused the lower risk or whether the people who received them differed in other ways, such as overall health or access to care.

“These findings are interesting, but like many of the other benefits associated with GLP-1 medications, a direct causal relationship has not yet been proven,” said Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center. “Rather, the benefits appear to be more closely tied to the reduction in obesity and better control of diabetes.”

Dementia risk
Photo: News-Medical

Alzheimer’s Trials Show No Benefit From Semaglutide

The review examined two large phase 3 trials, EVOKE and EVOKE+, which enrolled 3,808 adults with early Alzheimer’s disease. Participants received once-daily oral semaglutide up to 14 mg or placebo for 104 weeks. Semaglutide did not slow clinical decline or deterioration in daily function, though it shifted several Alzheimer’s-related biomarkers, including decreased cerebrospinal fluid levels of phosphorylated tau and neurogranin.

When Novo Nordisk announced the results in November 2025, research chief Martin Holst Lange said the company “felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success.”

A smaller phase 2b trial of liraglutide, an older GLP-1 drug, in 204 participants with mild-to-moderate Alzheimer’s over 52 weeks did not meet its primary endpoint of preserving cerebral glucose metabolism. Secondary findings suggested slower decline on a combined cognitive measure and less brain volume loss, but these findings require confirmation and were not accompanied by improvements in daily functioning.

Benefits May Depend on Patient Group and Timing

The review’s authors argue the trial failure in Alzheimer’s does not rule out cognitive benefits for other patients. People with obesity or type 2 diabetes often have trouble with attention, planning, and processing speed — problems the authors say are often tied to metabolism and blood vessel health rather than Alzheimer’s-related brain changes. Those problems, they suggest, may respond better to treatment.

Senior author Christoffer Clemmensen of the University of Copenhagen added: “Obesity medicines are becoming increasingly sophisticated, offering new opportunities to understand how metabolic regulation influences brain function. By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function.”

“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established,” Copenhagen said.

How the Drugs Might Reach the Brain

The review highlights uncertainty about how GLP-1 medications affect the brain. In animals, long-acting GLP-1 drugs preferentially reached brainstem and hypothalamic regions, while evidence of drug exposure in memory-associated regions such as the hippocampus or cortex was inconsistent. Neural signals from accessible brain regions could still influence cognitive networks.

GLP-1 receptor agonists
Photo: Healthline

“While research suggests GLP-1s could reduce brain inflammation, improve blood vessel health, and even protect neurons, much broader, randomized clinical trials on GLP-1s and brain health, including in people with Alzheimer’s disease and other dementias, are needed,” said Sheena Aurora, MD, vice president of Medical Affairs at the Alzheimer’s Association.

Heart Health, Lifestyle, and the Path Forward

The link between cardiovascular health and cognition remains central. Dung Trinh, MD, internist at MemorialCare Medical Group, said: “I often remind my patients that what’s good for the heart is generally good for the brain.” He explained that conditions such as high blood pressure, diabetes, obesity, and high cholesterol can damage blood vessels, promote chronic inflammation, and increase the risk of stroke and vascular cognitive impairment.

POINTER lifestyle intervention program can change heart health risk factors within 24 months, and better risk-factor control was linked with better cognition. The Alzheimer’s Association is now funding the PROTECT-Cog global phase 3 trial to evaluate whether combining a multidomain lifestyle intervention with a metabolism-targeting drug like a GLP-1 can further reduce the risk of cognitive decline in at-risk older adults.

Older adult cognitive assessment
Photo: Medical Daily

Risks for Older and Frail Patients

The authors flag a specific risk for older adults: rapid weight loss can reduce muscle mass, which may weaken physical function and offset potential cognitive benefits. For a caregiver, that could mean more falls or less independence rather than better memory.

The firm is now advancing a broader GLP-1 strategy that extends beyond diabetes and obesity; University of Copenhagen researcher Christoffer Clemmensen, collaborating with Novo Nordisk, noted that increasingly sophisticated obesity medicines offer new opportunities to understand how metabolic regulation influences brain function, aiming to disentangle direct and indirect drug effects to develop treatments specifically aimed at preserving cognitive function.

The researchers are calling for clinical trials that track memory and other thinking skills from the start of GLP-1 treatment to show whether these drugs protect everyday cognition rather than slow a specific brain disease.

Photo of author

Health Desk

Health Desk at Archyde.

Proposed 10% Credit Card Rate Cap May Undercut SoFi Personal Loan Product